



SpePharm establishes new subsidiary, SpeBio, to commercialise Loramyc® in Europe

SpeBio will market Loramyc® in Europe for the treatment of oropharyngeal candidiasis (OPC)

Amsterdam, The Netherlands and Paris, France, June 7, 2007 - SpePharm Holding, BV, the specialty pharmaceutical company dedicated to the sales and marketing of innovative hospital and specialists products throughout Europe, announced today that it has established a new subsidiary, SpeBio, to commercialize Loramyc® in Europe. This move is in keeping with the agreement signed on March 7, 2007 with BioAlliance Pharma, joint partner in the venture.

SpeBio BV, a fifty-fifty joint venture between SpePharm and BioAlliance, is to be based in The Netherlands and will commercialize Loramyc® in the European Union (with the exception of France), Norway and Switzerland. Loramyc® is indicated for the treatment of oropharyngeal candidiasis in immunocompromised patients and obtained a Marketing Authorisation for France in October 2006.

Under the terms of the agreements between SpePharm and BioAlliance, SpePharm will manage SpeBio, and provide the sales force and other resources in all concerned countries.

“We believe our collaboration with BioAlliance through SpeBio further validates SpePharm’s business model to maximize a product’s commercial possibilities in Europe, and we continue to advance our plans to build a pan-European specialty pharmaceutical company, active in the hospital and specialist segments”, said Jean-François Labbé, Founder and CEO of SpePharm.

“The setting up of SpeBio means we will be ready for the launch of Loramyc® once the mutual recognition procedure is completed,” said Dominique Costantini, President and CEO of BioAlliance.

-end-

Media contact:

SpePharm, BV

Jean-François LABBE

Managing Director

Tel: +33 (0) 1 56 60 52 46

jean-francois.labbe@spepharm.com

About SpePharm Holding, B.V.:

SpePharm Holding, B.V. is a Dutch company with its registered office in Amsterdam. SpePharm is an emerging pan-European specialty pharmaceutical company focused on the hospital and specialty markets, particularly in oncology, haematology, critical and supportive care and endocrinology. SpePharm was founded in September 2006 by Jean-François Labbé together with leading life science investment firms TVM Capital and Signet Healthcare Partners (part of the Sanders Morris Harris Group). Jean-François Labbé is a former top executive at Hoechst Marion Roussel and Parke Davis with over 30 years of experience in international pharmaceutical management.

For more information about SpePharm, please visit the web site at www.spepharm.com

About SpeBio, BV

SpeBio is established in The Netherlands as a 50/50 joint venture between SpePharm Holding, BV and BioAlliance Pharma, SA. The company has been established to commercialize Loramyc® in Europe, with the exception of France.

About Loramyc®

Loramyc® (miconazole Lauriad®) 50 mg, mucoadhesive buccal tablet has completed two Phase III clinical trials in Europe for the treatment of oropharyngeal candidiasis (OPC) in cancer and HIV patients. In October 2006, BioAlliance obtained a Marketing Authorization for the product in France.

About BioAlliance Pharma

BioAlliance Pharma, SA (Euronext Paris: BIO) is a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics targeting drug resistance in cancer, HIV, and opportunistic infections. For further information visit: www.bioalliancepharma.com